Related Experiment Video

Updated: Jun 27, 2026

Preterm EEG: A Multimodal Neurophysiological Protocol
19:32

Preterm EEG: A Multimodal Neurophysiological Protocol

Published on: February 18, 2012

[Infant biochemical and clinical parameters within the baby friendly programme]

Momrilo Dordevici1, Gordana Dordević, Bozidar Jovanović

  • 1Klinicki centar Kragujevac, Ginekolosko-akuserska klinika.

Medicinski Pregled
|December 23, 2008
PubMed

Insights

The baby-friendly program positively impacts infant health, reducing hypoglycemia, hypothermia, and weight loss. It also helps prevent thrush but does not affect bilirubin levels.

Area of Science:

  • Neonatal health
  • Pediatric nutrition
  • Infant care practices

Context:

  • Breastfeeding is crucial for infant health, growth, and development, with the initial hours post-childbirth being critical.
  • The baby-friendly program aims to optimize infant care and health outcomes during the early days of life.

Purpose:

  • To evaluate the effect of the baby-friendly program on infants' biochemical and clinical parameters in the first few days of life.
  • To determine if the baby-friendly program influences key infant health indicators such as glucose levels, temperature, weight, and the incidence of thrush and jaundice.

Summary:

  • The study compared 216 infants, assessing glycemia, bilirubinemia, temperature, stomatomycosis (thrush), and weight loss.
  • Infants not in the baby-friendly program showed significantly higher rates of hypoglycemia, hypothermia, weight loss, and thrush.
  • Bilirubin levels were not found to be dependent on the baby-friendly program.

Impact:

  • The baby-friendly program effectively reduces infant hypoglycemia, hypothermia, weight loss, and thrush.
  • Promoting frequent breastfeeding, as encouraged by the program, supports glucose homeostasis and reduces infant cooling.
  • The program's positive effects on infant health parameters highlight its importance in neonatal care.
Abstract

More Related Videos

Biochemical Measurement of Neonatal Hypoxia13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Application of an Amplitude-integrated EEG Monitor (Cerebral Function Monitor) to Neonates05:58

Application of an Amplitude-integrated EEG Monitor (Cerebral Function Monitor) to Neonates

Published on: September 6, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...